Adaptive Biotechnologies ADPT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$20.02M-47.4% | -$13.58M-242% | $9.55M+137% | -$25.59M+14.2% | -$29.83M+11.5% | ||
| $3.42M-9.2% | $3.77M-5.3% | $3.98M-2.5% | $4.08M-5.4% | $4.31M+7.3% | ||
| $11.93M-6.2% | $12.72M-4.1% | $13.26M-0.8% | $13.36M+10.0% | $12.15M-5.3% | ||
| -$2.05M-137% | $5.54M+934% | $536K-23.6% | $702K-62.3% | $1.86M+107% | ||
| $1.32M+13,050% | $10K-99.3% | $1.35M+1,518% | -$95K+64.0% | -$264K+92.2% | ||
| -$7.51M-745% | $1.17M— | —— | —— | -$9.67M-327% | ||
| $824K— | —— | $2.52M+408% | $497K+202% | -$489K+49.1% | ||
| $98K+172% | -$137K— | $0+100% | -$11K-283% | $6K+220% | ||
| $4M— | $0+100% | -$32.79M-665% | -$4.29M-28.9% | -$3.33M-96.6% | ||
| $419K-2.3% | $429K+0.2% | $428K+1.2% | $423K+1.0% | $419K-2.1% | ||
| -$9.54M— | $0+100% | -$7.13M+42.7% | -$12.43M+56.4% | -$28.48M-128% | ||
| $796K+25.2% | $636K+55.5% | $409K-37.6% | $655K-48.0% | $1.26M+1,474% | ||
| $9.14M— | —— | $17.28M+417% | $3.35M-86.9% | $25.57M+15.6% | ||
| $5.03M-45.0% | $9.13M+442% | $1.68M+4.6% | $1.61M-70.5% | $5.45M+4,192% | ||
| $7.5M-65.4% | $21.66M+1,186% | $1.68M+4.6% | $1.61M-70.5% | $5.45M+4,192% | ||
| $7.11M-54.0% | $15.46M+30.6% | $11.84M+258% | -$7.47M-394% | $2.54M— | ||
| $3.58M-23.7% | $4.7M+59.6% | $2.94M+12.3% | $2.62M+10.5% | $2.37M+2.2% | ||
| $136K-52.8% | $288K-44.2% | $516K-31.2% | $750K-21.7% | $958K-34.3% | ||
| $419K-2.3% | $429K+0.2% | $428K+1.2% | $423K+1.0% | $419K-2.1% | ||
| $3.42M-9.2% | $3.77M-5.3% | $3.98M-2.5% | $4.08M-5.4% | $4.31M+7.3% | ||
| $347K— | $0— | —— | —— | $0— | ||
| -$2.6M+2.1% | -$2.66M-3.4% | -$2.57M+19.7% | -$3.2M-57.0% | -$2.04M+31.4% | ||
| $824K— | —— | $2.52M+408% | $497K+202% | -$489K+49.1% | ||
| -$10K— | —— | —— | —— | -$101K-121% | ||
| $1.45M+5.5% | $1.37M+1.6% | $1.35M+1.4% | $1.33M+1.5% | $1.31M+1.5% | ||
| -$14K+86.1% | -$101K+76.7% | -$434K— | $0+100% | -$76K— | ||
| $655K— | —— | —— | —— | -$283K+56.8% | ||
| $2.48M— | —— | —— | —— | $0— | ||
| $159K— | —— | $444K+3,315% | $13K-93.8% | $211K-83.1% | ||
| -$10.33M— | $0+100% | -$7.54M+42.4% | -$13.09M+56.0% | -$29.74M-137% | ||
| -$10.33M— | $0+100% | -$7.54M+42.4% | -$13.09M+56.0% | -$29.74M-137% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Adaptive Biotechnologies generate?
- Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Adaptive Biotechnologies's free cash flow?
- After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
- Where does Adaptive Biotechnologies's cash flow data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
